154 related articles for article (PubMed ID: 27235014)
1. Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice.
Tsuboi K; Hasegawa T; Yamamoto T; Sasaki M; Hongo H; de Freitas PH; Shimizu T; Takahata M; Oda K; Michigami T; Li M; Kitagawa Y; Amizuka N
Histochem Cell Biol; 2016 Sep; 146(3):337-50. PubMed ID: 27235014
[TBL] [Abstract][Full Text] [Related]
2. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
Plotkin LI; Lezcano V; Thostenson J; Weinstein RS; Manolagas SC; Bellido T
J Bone Miner Res; 2008 Nov; 23(11):1712-21. PubMed ID: 18597631
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.
Plotkin LI; Gortazar AR; Davis HM; Condon KW; Gabilondo H; Maycas M; Allen MR; Bellido T
J Biol Chem; 2015 Jul; 290(31):18934-42. PubMed ID: 26085098
[TBL] [Abstract][Full Text] [Related]
4. Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.
Alasmari A; Lin SC; Dibart S; Salih E
Clin Exp Metastasis; 2016 Aug; 33(6):563-88. PubMed ID: 27155840
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
Cui P; Liu H; Sun J; Amizuka N; Sun Q; Li M
Histol Histopathol; 2018 Jan; 33(1):89-99. PubMed ID: 28345127
[TBL] [Abstract][Full Text] [Related]
6. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
Plotkin LI; Manolagas SC; Bellido T
Bone; 2006 Sep; 39(3):443-52. PubMed ID: 16627025
[TBL] [Abstract][Full Text] [Related]
8. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
Follet H; Li J; Phipps RJ; Hui S; Condon K; Burr DB
Bone; 2007 Apr; 40(4):1172-7. PubMed ID: 17240209
[TBL] [Abstract][Full Text] [Related]
9. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
Uveges TE; Kozloff KM; Ty JM; Ledgard F; Raggio CL; Gronowicz G; Goldstein SA; Marini JC
J Bone Miner Res; 2009 May; 24(5):849-59. PubMed ID: 19113917
[TBL] [Abstract][Full Text] [Related]
10. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
Iwata K; Li J; Follet H; Phipps RJ; Burr DB
Bone; 2006 Nov; 39(5):1053-1058. PubMed ID: 16807159
[TBL] [Abstract][Full Text] [Related]
12. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.
Plotkin LI; Weinstein RS; Parfitt AM; Roberson PK; Manolagas SC; Bellido T
J Clin Invest; 1999 Nov; 104(10):1363-74. PubMed ID: 10562298
[TBL] [Abstract][Full Text] [Related]
13. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice.
Plotkin LI; Bivi N; Bellido T
Bone; 2011 Jul; 49(1):122-7. PubMed ID: 20736091
[TBL] [Abstract][Full Text] [Related]
14. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
15. Modulation of murine bone marrow-derived CFU-F and CFU-OB by in vivo bisphosphonate and fluoride treatments.
Chou MY; Yan D; Jafarov T; Everett ET
Orthod Craniofac Res; 2009 May; 12(2):141-7. PubMed ID: 19419457
[TBL] [Abstract][Full Text] [Related]
16. The effects of mechanically loaded osteocytes and inflammation on bone remodeling in a bisphosphonate-induced environment.
George EL; Truesdell SL; Magyar AL; Saunders MM
Bone; 2019 Oct; 127():460-473. PubMed ID: 31301402
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous delivery of BMP-2 factor and anti-osteoporotic drugs using hyaluronan-assembled nanocomposite for synergistic regulation on the behaviors of osteoblasts and osteoclasts in vitro.
Zhang Y; Hu Y; Luo Z; Shen X; Mu C; Cai K
J Biomater Sci Polym Ed; 2015; 26(5):290-310. PubMed ID: 25585099
[TBL] [Abstract][Full Text] [Related]
18. Effect of Alendronate on Bone Formation during Tooth Extraction Wound Healing.
Tanoue R; Koi K; Yamashita J
J Dent Res; 2015 Sep; 94(9):1251-8. PubMed ID: 26124220
[TBL] [Abstract][Full Text] [Related]
19. Injectable nanoparticle-loaded hydrogel system for local delivery of sodium alendronate.
Posadowska U; Parizek M; Filova E; Wlodarczyk-Biegun M; Kamperman M; Bacakova L; Pamula E
Int J Pharm; 2015 May; 485(1-2):31-40. PubMed ID: 25747455
[TBL] [Abstract][Full Text] [Related]
20. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Gangoiti MV; Cortizo AM; Arnol V; Felice JI; McCarthy AD
Eur J Pharmacol; 2008 Dec; 600(1-3):140-7. PubMed ID: 18973752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
